Some people living with high cholesterol have already tried two or three medications. They take a pill every morning, get their blood drawn every few months, adjust their dose, and still can’t get their LDL – that’s low-density lipoprotein, or “bad” cholesterol – down to a safe level. For them, a single infusion that could permanently silence the root problem isn’t a fantasy. Researchers just showed it might be possible.
A one-time cholesterol drug that edits your DNA sounds like science fiction, but the first human trial data published in late 2025 suggest it actually works. Researchers used CRISPR-Cas9, a molecular tool that can find a specific gene in your cells and switch it off permanently, to slash LDL cholesterol and triglycerides in people who had run out of conventional options. The results exceeded what the trial team expected.
The drug is called CTX310. It doesn’t add anything to the body, and it doesn’t need to be taken daily. It goes in once, finds its target in the liver, and the gene it silences stays silent. Understanding how it does that and what we still don’t know matters a lot before placing too much weight on a 15-person trial.
The Gene Nobody Talks About, and Why Switching It Off Helps
The target of CTX310 is a gene called ANGPTL3 (angiopoietin-like protein 3). CTX310 is delivered via nanoparticles that carry CRISPR instructions to liver cells, where the editing tool disables ANGPTL3, a gene that codes for a protein that inhibits the breakdown of triglycerides and LDL cholesterol. Switch the gene off, and the liver becomes better at clearing both types of fat from the blood.
The logic for targeting ANGPTL3 comes from decades of genetic research. Turning off this gene lowers LDL and triglycerides, two blood fats linked to heart disease, and people born with natural mutations that turn off ANGPTL3 have lifelong low cholesterol and triglyceride levels without apparent harmful effects, along with a lower lifetime risk of atherosclerotic cardiovascular disease. Atherosclerotic cardiovascular disease is the buildup of plaque in the arteries that leads to heart attacks and strokes. Essentially, some people are walking around with a naturally switched-off version of this gene, living longer and healthier lives for it. CTX310 tries to replicate that biology artificially.
Detailed phenotyping in people with complete ANGPTL3 deficiency found an absence of coronary atherosclerotic plaque, and a large genomic analysis in up to 180,000 individuals found a 34% reduction in risk of coronary artery disease among those carrying loss-of-function variants. That’s the evidence base behind the therapy: a genetic precedent showing the body can handle losing this gene, with no known downside.
What the Trial Actually Found
The study ran between June 2024 and August 2025 at six sites in Australia, New Zealand, and the United Kingdom. According to the American Heart Association’s newsroom, in the 15-patient, Phase 1 first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol and triglycerides in people with difficult-to-treat lipid disorders.
CTX310 was delivered as a one-time infusion. All participants were adults whose lipid levels remained uncontrolled despite maximum tolerated existing therapies – meaning statins, cholesterol-absorption blockers, and in some cases PCSK9 inhibitors (injectable drugs that boost LDL clearance) had already been tried. According to the official press release from CRISPR Therapeutics, a single course of treatment produced mean reductions in ANGPTL3 of 73%, mean LDL reductions of 49%, and mean triglyceride reductions of 55% at the highest dose.
Researchers said the results were stronger than expected: a 30-40% reduction would have been considered a success, yet CTX310 reduced both LDL and triglycerides by nearly 50% or more on average at the highest dose.
The durability of those reductions is what makes this a one-time cholesterol drug rather than just another therapy. LDL cholesterol and triglyceride levels were substantially reduced within two weeks after treatment and stayed at low levels for at least 60 days, with additional follow-up ongoing. The reductions were also dose-dependent – meaning higher doses produced larger and more consistent results – which is exactly the kind of pattern researchers want to see in a Phase 1 trial.
Researchers noted that CTX310 is the first therapy to achieve large simultaneous reductions in both LDL cholesterol and triglycerides, a significant advance for patients with mixed lipid disorders who typically carry elevations in both.
The results were presented during a late-breaking science presentation at the American Heart Association’s Scientific Sessions 2025 and simultaneously published in the New England Journal of Medicine.
The Safety Picture – Promising, With Caveats
Participants were followed for safety of the treatment, how the gene therapy was processed in the body, and cholesterol and triglyceride levels. The short-term safety profile was clean. CTX310 was well tolerated with no treatment-related serious adverse events and no Grade 3 or higher changes in liver transaminases – liver transaminases are enzymes whose elevation in the blood signals liver stress or damage.
Three participants did experience mild infusion reactions. According to the American Heart Association’s 2025 Heart Disease and Stroke Statistics, an estimated 86.4 million U.S. adults – about 35% – have total cholesterol levels of 200 mg/dL or higher. One in four Americans over 40 already takes a statin to reduce their risk of heart attack, ischemic stroke, and related complications – yet for those who can’t tolerate or can’t adequately respond to statins, long-term adherence is far from optimal, with discontinuation estimated to occur in roughly 10% of U.S. patients. A therapy requiring only one dose removes that adherence problem entirely.
Some researchers expressed concerns about potential liver toxicities with treatments like this, and there’s also a broader question of how many patients would want a permanent gene edit for a condition that might otherwise be managed with a daily pill or injection. Those are fair questions for a 15-person trial in people who had already exhausted their other options.
The FDA‘s position on therapies like this reflects those concerns. Because CRISPR-Cas9 can durably change DNA inside cells, the FDA recommends long-term safety monitoring, typically up to 15 years, for all studies using CRISPR-based therapies. Patients in this trial will be monitored for one year within the study, followed by 15 years of additional long-term safety follow-up. That’s not a red flag – it’s standard protocol for any therapy that makes permanent changes at the genetic level.
The Scale of the Problem CTX310 Is Trying to Solve
High cholesterol is a major risk factor for heart disease and stroke, the leading causes of death worldwide. The 2025 AHA statistics report puts the number of U.S. adults with total cholesterol of 200 mg/dL or higher at approximately 86.4 million – roughly 35% of the adult population.
More than 40 million people in the United States have elevated triglycerides, elevated LDL cholesterol, or both. The people enrolled in this trial represent the hardest cases – those for whom current medicine has effectively run out of moves. But if CTX310 proves safe and effective in larger trials, it could apply much more broadly.
The adherence argument is real. In real-world studies, adherence to statin therapy can fall below 50% within the first year of treatment, far lower than rates seen in controlled clinical trials. A treatment that requires no ongoing compliance removes one of the biggest practical obstacles in cardiovascular medicine.
Additional Data and What Comes Next
The November 2025 presentation wasn’t the only data point on CTX310. Additional Phase 1 clinical data reported earlier in 2025 showed continued dose-dependent reductions in triglycerides and LDL, with peak reductions of up to 82% in triglycerides and up to 86% in LDL, with a well-tolerated safety profile. Those are peak figures from the highest-dose patients, not averages – but they signal what the ceiling might look like if optimization continues.
CRISPR Therapeutics has advanced CTX310 into Phase 1b clinical trials, focusing on patients with severe hypertriglyceridemia (dangerously high triglycerides) and refractory hypercholesterolemia (cholesterol that resists every available treatment). According to a January 2026 announcement from CRISPR Therapeutics, the company expects to provide a program update in the second half of 2026.
If you want context on how diet and lifestyle interact with the medications your doctor may already have you on, this breakdown of the worst foods for cholesterol covers what the research consistently flags.
Read More: The Top 22 Foods To Avoid for Better Cholesterol Health, According to Experts
What This Means for You
This is a Phase 1 trial. That means it was designed primarily to test safety and to find the right dose, not to prove effectiveness in the general population. Fifteen participants is a tiny number. The follow-up period – 60 days for the lipid data – is short. The FDA’s 15-year monitoring requirement exists precisely because the long-term effects of permanently editing a gene in living humans are not yet known.
With those limits stated plainly: the early signal here is genuinely strong. The reductions in LDL and triglycerides exceeded what the trial team hoped for. The safety profile in this first group showed no serious adverse events related to the treatment. The biological rationale is solid – people who naturally lack ANGPTL3 function appear to benefit without harm. And the adherence problem that undermines current cholesterol treatment is, by definition, solved by a one-time drug.
If you’re currently managing high cholesterol or triglycerides, the practical takeaway right now is not to wait for CTX310 – Phase 1b trials are underway, and any approved therapy is years away. The practical step today is to ask your doctor whether your current regimen is achieving your LDL target and whether you’re a candidate for newer treatments like PCSK9 inhibitors if first-line therapies haven’t been enough. For the subset of patients who truly can’t get their lipids under control with existing options, CTX310 may eventually represent the option that current medicine can’t offer. The early data say it’s worth taking seriously.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Cardiologist Recommend Six morning Habits to Lower Cholesterol